Your browser is out of date

With an updated browser, you will have a better Medtronic website experience. Update my browser now.

×

Skip to main content

Patient selection

Renal denervation for hypertension

The Symplicity™ blood pressure procedure can help a wide range of patients you see in daily clinical practice.

Contact us
Alert Indications, Safety, and Warnings

Select ideal patients for the Symplicity procedure

Patients who may be candidates for the Symplicity blood pressure procedure tend to fall into one of three groups. Typically, these patients are open to a balanced conversation about the procedure that takes their preferences into account.

The numeral one represents the first step in the process of building a hypertension program.

Difficult to control

Patients who take multiple anti-hypertensive medications and are rigorously adherent — yet still not able to control their blood pressure (BP) — are often ready for a different treatment approach.2

The numeral two represents the second step in the process of building a hypertension program.

Unwilling or unable to adhere

The more medications patients take, the lower their adherence.2-4 Non- adherence doubles when patients move from two to three pills.2-4 These factors may explain why nearly half of patients become non-adherent within one year.5

The numeral three represents the third step in the process of building a hypertension program.

Motivated

Factors driving preference for the Symplicity blood pressure procedure tend to be associated with how clearly the patient understands the benefits of blood pressure reduction. These factors include:

  • Personal experiences have made high blood pressure consequences real.2
  • Perceive high blood pressure as a significant risk.2
  • Blood pressure medication side effects have negatively impacted their lives.2

Experts recommend renal denervation

A growing number of expert position and consensus statements from medical societies worldwide are shaping patient selection criteria for renal denervation, including the Symplicity blood pressure procedure.

Review global guidelines

The position is clear

A position paper from the European Society of Hypertension recommends renal denervation as an evidence-based treatment option for a wide range of patients.1

Read the ESH paper
A white logo for the European Society of Hypertension on a gray background.

Growing consensus on renal denervation

Jose Garcia-Donaire, M.D., reviews global consensus statements that can help identify the right patients for renal denervation, including the Symplicity blood pressure procedure.

Insights on patient selection

Professor Isabella Sudano, PhD, discusses which patients are best suited for the Symplicity blood pressure procedure, including how to incorporate patient preference.

Real-world RDN patient selection

This three-part series from Radcliffe Medical Education covers practical applications of RDN guidelines for patients with resistant hypertension. CME accredited.

Register for the course
Four experts featured in a three-part CME accredited series from Radcliffe Medical Education about patient selection for RDN.

Why patient preference matters

Patients with hypertension may see the Symplicity
blood pressure procedure differently than physicians,
and many may prefer a procedural approach even if
they are not taking anti-hypertensive medications.2

Download manuscript
Take action on hypertension by building a dedicated program.

Build your HTN program

Explore resources for introducing the Symplicity blood pressure procedure to your community.

Take action on HTN
Two text bubble icons represent the availability of patient education materials.

Explain the risks of HTN

Educate your patients about the risks of hypertension and why the Symplicity blood pressure procedure may be the right choice.

Find patient resources
1

Schmieder R, Mahfoud F, Mancia G, et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9):1733-1741.

2

Schmieder R, Kandzari D, Wang TD, et. al. Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. J Hypertens. 2020. Doi:10.1097/HJH.0000000000002592.

3

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339.

4

Schmieder RE, Mahfoud F, Azizi M, et al. European Society of Hypertension position paper on renal denervation 2018. J Hypertens. 2018;36(10):2042-2048.

5

Bruno RM, Taddei S, Borghi C, et al. Italian Society of Arterial Hypertension (SIIA) position paper on the role of renal denervation in the management of the difficult-to-treat hypertensive patient. High Blood Press Cardiovasc Prev. 2020;27:109-117.